Stryker Corporation (NYSE:SYK) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Stryker Corporation (NYSE:SYK) have been given an average rating of “Moderate Buy” by the eighteen analysts that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $426.4706.

Several equities analysts have weighed in on SYK shares. TD Cowen lowered shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 target price on the stock. in a report on Monday, January 26th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 price objective on shares of Stryker in a report on Friday, November 14th. BTIG Research raised their target price on Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Piper Sandler restated an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th. Finally, Truist Financial decreased their price target on Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares in the last quarter. Schnieders Capital Management LLC. purchased a new stake in Stryker during the second quarter worth about $205,000. Daymark Wealth Partners LLC lifted its position in shares of Stryker by 7.4% during the second quarter. Daymark Wealth Partners LLC now owns 7,306 shares of the medical technology company’s stock worth $2,890,000 after purchasing an additional 501 shares in the last quarter. Arkadios Wealth Advisors boosted its stake in shares of Stryker by 17.2% in the second quarter. Arkadios Wealth Advisors now owns 4,747 shares of the medical technology company’s stock valued at $1,878,000 after purchasing an additional 695 shares during the period. Finally, Premier Path Wealth Partners LLC grew its holdings in shares of Stryker by 4.4% in the second quarter. Premier Path Wealth Partners LLC now owns 1,746 shares of the medical technology company’s stock valued at $691,000 after purchasing an additional 73 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE SYK opened at $386.04 on Friday. Stryker has a twelve month low of $329.16 and a twelve month high of $404.87. The stock has a market capitalization of $147.73 billion, a price-to-earnings ratio of 45.96, a PEG ratio of 2.24 and a beta of 0.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average of $362.53 and a 200 day moving average of $369.14.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. During the same quarter in the prior year, the firm earned $4.01 earnings per share. The business’s revenue was up 11.4% compared to the same quarter last year. Sell-side analysts anticipate that Stryker will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 41.90%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.